NCT07089550Recruiting
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN), an Italian Multicenter Study
Source: ClinicalTrials.gov · Last updated 20 Feb 2026
Brief summary (registry, in English)
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies. The primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population. This study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1300 (estimated)
- First submitted
- 28 May 2025
- Start date
- 2 Apr 2025
- Primary completion date
- 26 Apr 2034
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Prostate cancer
- NCT number
- NCT07089550
What you commit to
- Study type: Observational
- Planned participants: 1300
- From 2 Apr 2025 to the primary completion date, 26 Apr 2034
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of another concurrent malignancy, with the exception of non-melanoma skin cancer.
Other illness
- Prostate cancer with a known significant neuroendocrine component;
Other
- Inability to remain supine and still for the PET/CT image acquisition;
Who the study is looking for
- Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma);
- Patients undergoing PSMA PET for pre-treatment disease staging;
- Candidates to receive one or more of the following systemic therapies, in combination or alone: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA;
- Provision of signed informed consent for study participation and data handling.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Recruiting |
| Azienda Ospedaliera Santa Croce e Carle - ospedale Santa Croce Coordinator of this site? Confirm its status | Cuneo | Italy | Recruiting |
| U.O. Medicina Nucleare, IRCCS Ospedale Policlinico San Martino Coordinator of this site? Confirm its status | Genova | Italy | Recruiting |
| UOC Medicina Nucleare, AOU Policlinico G.Martino Coordinator of this site? Confirm its status | Messina | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.